TRAW Traws Pharma, Inc.
Price Chart
Executive Summary
Traws Pharma announced a $10.0 million PIPE financing with new and existing investors, accompanied by up to $50 million in potential future proceeds from milestone-based and three-year warrants. The funding is intended to support completion of the Company's UK-based Challenge trial for its respiratory viral therapy program.
Key Financial Metrics
Actionable Insight
The $10M PIPE provides near-term runway for the pivotal Challenge trial; traders should monitor trial milestones as they could trigger warrant exercises and additional dilution. Given the company's $13M market cap, this financing materially strengthens liquidity and de-risks development.
Key Facts
- Traws Pharma secured $10.0 million in gross proceeds through a PIPE financing.
- Additional $50 million in gross proceeds available via milestone-based and three-year warrants.
- Funds will support completion of the Challenge trial in the UK.
- Investors include both new and existing institutional and accredited investors.
Financial Impact
$10.0 million immediate capital raise with potential for $50 million in follow-on proceeds via warrants
Risk Factors
- Potential significant dilution if milestone or long-term warrants are exercised.
- Clinical trial failure could impair valuation despite increased cash reserves.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
8-K
| $1.29 awaiting T+5 | awaiting T+5 | — | $1.28 (+0.78%) |
|
May 29, 2026
14d ago
|
DEFA14A
| $1.46 $1.45 | ▼ −0.68% | ▼ −0.39% | $1.28 (−12.33%) |
|
May 27, 2026
16d ago
|
8-K
| $1.53 $1.42 | ▼ −7.19% | ▼ −8.40% | $1.28 (−16.34%) |
|
May 26, 2026
17d ago
|
8-K
| $1.53 $1.45 | ▼ −5.23% | ▼ −5.70% | $1.28 (−16.34%) |
|
May 22, 2026
22d ago
|
424B5
| $1.49 $1.47 | ▲ +1.34% | ▲ +3.02% | $1.28 (+14.09%) |
|
May 18, 2026
26d ago
|
EFFECT
| $1.76 $1.58 | ▲ +10.23% | ▲ +11.85% | $1.28 (+27.27%) |
|
May 15, 2026
29d ago
|
8-K
| $1.88 $1.49 | ▲ +20.74% | ▲ +21.71% | $1.28 (+31.91%) |
|
May 15, 2026
29d ago
|
Press Release
| $1.88 $1.49 | ▼ −20.74% | ▼ −21.71% | $1.28 (−31.91%) |
|
May 8, 2026
5w ago
|
S-3
| $2.02 $1.76 | ▲ +12.87% | ▲ +12.79% | $1.28 (+36.63%) |
|
May 8, 2026
5w ago
|
Press Release
| $2.18 $1.63 | ▼ −25.23% | ▼ −26.69% | $1.28 (−41.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access